These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37805954)

  • 21. Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.
    Woo V
    Int J Clin Pract; 2015 Dec; 69(12):1427-37. PubMed ID: 26303997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data.
    Del Parigi A; Tang W; Liu D; Lee C; Pratley R
    Pharmaceut Med; 2019 Jun; 33(3):209-217. PubMed ID: 31933292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study.
    Liu SC; Lee CC; Chuang SM; Sun FJ; Zeng YH
    Diabetes Metab; 2021 May; 47(3):101184. PubMed ID: 32827752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.
    Gallwitz B
    Expert Opin Drug Saf; 2017 Dec; 16(12):1399-1405. PubMed ID: 28934557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
    Forst T; Falk A; Andersen G; Fischer A; Weber MM; Voswinkel S; Heise T; Kapitza C; Plum-Mörschel L
    Diabetes Obes Metab; 2017 Apr; 19(4):489-495. PubMed ID: 28009472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
    Kawamori R; Haneda M; Suzaki K; Cheng G; Shiki K; Miyamoto Y; Solimando F; Lee C; Lee J; George J
    Diabetes Obes Metab; 2018 Sep; 20(9):2200-2209. PubMed ID: 29766636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study.
    Inagaki N; Nishimoto T; Nishiya Y; Nitta D
    Expert Opin Drug Saf; 2023 Feb; 22(2):153-163. PubMed ID: 35946927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-pill Combination of Empagliflozin and Linagliptin in Real World Indian Type 2 Diabetes Patient (GRID).
    Kovil R; Saboo B; Shah K; Padhye D; Chudasama D; Raj V; Shaikh N
    J Assoc Physicians India; 2020 Oct; 68(10):53-55. PubMed ID: 32978926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
    Korbut AI; Taskaeva IS; Bgatova NP; Muraleva NA; Orlov NB; Dashkin MV; Khotskina AS; Zavyalov EL; Konenkov VI; Klein T; Klimontov VV
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
    Kern M; Klöting N; Mark M; Mayoux E; Klein T; Blüher M
    Metabolism; 2016 Feb; 65(2):114-23. PubMed ID: 26773934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin.
    Zeng YH; Liu SC; Lee CC; Sun FJ; Liu JJ
    Sci Rep; 2022 Oct; 12(1):17065. PubMed ID: 36224294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Innovative UV Protocols Based on Straightforward Mathematical Filtration for Concurrent Estimation of Two Antidiabetic Drugs in Their Brand-New Combination: A Comparative Study.
    Nour IM; Mohamed AR; Badrawy M
    J AOAC Int; 2024 Jan; 107(1):40-45. PubMed ID: 37824214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
    Ott C; Jung S; Korn M; Kannenkeril D; Bosch A; Kolwelter J; Striepe K; Bramlage P; Schiffer M; Schmieder RE
    Cardiovasc Diabetol; 2021 Sep; 20(1):178. PubMed ID: 34481498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.
    Kaku K; Haneda M; Tanaka Y; Lee G; Shiki K; Miyamoto Y; Solimando F; Lee J; Lee C; George J
    Diabetes Obes Metab; 2019 Jan; 21(1):136-145. PubMed ID: 30091172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
    Laffel LM; Danne T; Klingensmith GJ; Tamborlane WV; Willi S; Zeitler P; Neubacher D; Marquard J;
    Lancet Diabetes Endocrinol; 2023 Mar; 11(3):169-181. PubMed ID: 36738751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simple mathematical data processing method for the determination of sever overlapped spectra of linagliptin and empagliflozin in their pure forms and pharmaceutical formulation: Fourier self deconvulated method.
    Elmasry MS; Hassan WS; Merey HA; Nour IM
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Jun; 254():119609. PubMed ID: 33684852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In brief: Trijardy XR - a new 3-drug combination for Type 2 diabetes.
    Med Lett Drugs Ther; 2020 Jun; 62(1599):88. PubMed ID: 32555117
    [No Abstract]   [Full Text] [Related]  

  • 38. Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.
    Jung S; Bosch A; Kannenkeril D; Karg MV; Striepe K; Bramlage P; Ott C; Schmieder RE
    Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):364-371. PubMed ID: 31816038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Retrospective Analysis of Fixed Combination of Empagliflozin and Linagliptin in Addition to the Existing Treatment for its Clinical Effectiveness in Adults with Type 2 Diabetes: A Real-World Clinical Experience.
    Gupta A; Malhotra P; Jamwal V; Khalse M
    J Assoc Physicians India; 2021 Jul; 69(7):11-12. PubMed ID: 34431269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial.
    Laursen JC; Rotbain Curovic V; Kroonen MYAM; Jongs N; Zobel EH; Hansen TW; Frimodt-Møller M; Laverman GD; Kooy A; Persson F; Heerspink HJL; Hansen CS; Rossing P
    Diabetes Obes Metab; 2023 Oct; 25(10):3064-3067. PubMed ID: 37385968
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.